Literature DB >> 2403420

Synergistic effect of the v-myc oncogene with H-ras on radioresistance.

W G McKenna1, M C Weiss, B Endlich, C C Ling, V J Bakanauskas, M L Kelsten, R J Muschel.   

Abstract

Resistance of tumors to irradiation or chemotherapeutic agents is thought to be one of the reasons why patients who present with early malignancies may not be cured. Much is now known about the molecular mechanisms that underlie drug resistance, but until recently little was known about genetic contributions to radiation resistance. Some evidence now links oncogenes, particularly the ras family of oncogenes, to radiation resistance but heterogeneity between tumors and cell lines has complicated this analysis. Primary rat embryo cells have been chosen as a model system in which the effects on radiation resistance of the H-ras oncogene could be studied on a uniform genetic background. These cells offer several useful advantages. The cells prior to transformation are diploid, and because they have been in culture only for a few passages prior to transformation with the oncogene it is unlikely that any preexisting mutation affecting radiation response could be present. Additionally, the use of rat embryo cells permitted the study of the effects of a second oncogene on the appearance of the radioresistant phenotype. The results show that the activated H-ras oncogene is associated with radiation resistance in primary rat cells after transformation but that the effect of the oncogene by itself is small. However, the oncogene v-myc, which has no effect on radiation resistance by itself, has a synergistic effect on radiation resistance with H-ras. There appear to be differences in the phenotype of radiation resistance associated with these two forms of transfectants. Thus, radiation resistance seen with H-ras by itself is characterized by a change in the slope of the radiation survival curve at high radiation doses but little or no change within the should region of the radiation survival curve. Radiation resistance seen in H-ras plus v-myc transformants is also characterized by an increase in the slope of the curve at high doses but there is also a large effect within the shoulder region of the radiation survival curve. These studies led to the following conclusions: (a) the radioresistant phenotype is not due to preexisting genetic heterogeneity in the cells prior to transfection; (b) the radiation resistant phenotype of cells transformed by H-ras is seen to a greater degree in cells which also contain the v-myc oncogene; (c) the v-myc oncogene may play an important role in the phenotype of radiation resistance at low doses that is within the range most critical for clinical practice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403420

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Signaling pathways in NSCLC as a predictor of outcome and response to therapy.

Authors:  Anjali K Gupta; Daniel E Soto; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Stephen M Hahn; Mitchell Machtay; Ruth J Muschel; W Gillies McKenna
Journal:  Lung       Date:  2004       Impact factor: 2.584

2.  MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Authors:  Francesco Marampon; Giovanni Luca Gravina; Agnese Di Rocco; Pierluigi Bonfili; Mario Di Staso; Caterina Fardella; Lorella Polidoro; Carmela Ciccarelli; Claudio Festuccia; Vladimir M Popov; Richard G Pestell; Vincenzo Tombolini; Bianca Maria Zani
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

3.  Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

Authors:  Pradip De; Yuling Sun; Jennifer H Carlson; Lori S Friedman; Brian R Leyland-Jones; Nandini Dey
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

4.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.

Authors:  Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 5.  Genetic and epigenetic features in radiation sensitivity Part I: cell signalling in radiation response.

Authors:  Michel H Bourguignon; Pablo A Gisone; Maria R Perez; Severino Michelin; Diana Dubner; Marina Di Giorgio; Edgardo D Carosella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02       Impact factor: 9.236

6.  Role of inducible heat shock protein 70 in radiation-induced cell death.

Authors:  S J Lee; S A Choi; K H Lee; H Y Chung; T H Kim; C K Cho; Y S Lee
Journal:  Cell Stress Chaperones       Date:  2001-07       Impact factor: 3.667

Review 7.  The biology of radioresistance: similarities, differences and interactions with drug resistance.

Authors:  S N Powell; E H Abraham
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

8.  Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells.

Authors:  D M O'Rourke; G D Kao; N Singh; B W Park; R J Muschel; C J Wu; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

Authors:  P A van Dam; I B Vergote; D G Lowe; J V Watson; P van Damme; J C van der Auwera; J H Shepherd
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

10.  A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.

Authors:  Michelle Alonso-Basanta; Penny Fang; Amit Maity; Stephen M Hahn; Robert A Lustig; Jay F Dorsey
Journal:  J Neurooncol       Date:  2013-11-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.